In this edition of Essential, we’ve got updates on some big compounding news — like the FDA’s long-overdue decision to remove the boxed warning from some menopause hormone-replacement therapy drugs. (And yes, that’s important for compounding pharmacists!) We also look at the hubbub at FDA over what (allegedly) was behind the decision that would have effectively banned compounding with desiccated thyroid extract, plus some stories from the states, and more. This month’s deep dive: Mythbusting, compounded-GLP-1 style! What have the big drugmakers been saying, and how much of it is true? They’re spreading stories, but our experts put them to the test. Don’t miss out! Links Join APC today: https://a4pc.org/membership FDA to remove boxed warning from HRT medications: https://archive.ph/R8DJD An example of what appears to be an op-ed pushed by a pharma company. The writer, a “former healthcare professional,”doesn’t appear to exist: https://archive.ph/OPNWr Find a legitimate, licensed compounding pharmacy: https://a4pc.org/isitlegit Benefits of becoming an APC PFM: https://a4pc.org/pfm
